Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NST-11
- Development stage
- Preclinical
- Lead developer
- Novasenta
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
NST-11 is a preclinical-stage antibody-based therapeutic being developed by Novasenta for applications in immuno-oncology. Discovered through Novasenta's proprietary discovery platform, which focuses on identifying novel targets within the tumor microenvironment (TME), NST-11 is designed to modulate anti-tumor immune responses by interacting with a specific, currently undisclosed, immune cell target. The program is part of a pipeline aimed at addressing unmet needs in cancer treatment by leveraging unique insights into the complex interactions between the immune system and solid tumors. As of current public disclosures, the drug is undergoing preclinical evaluation to support future clinical development.
Beyond the preview
Go deeper on NST-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NST-11.